View Cart  

Alimera’s Thrice-Rejected Eye Drug Iluvien Finally Gets FDA Approval

The company plans to launch the drug in the first quarter of next year. Read More

Baxter to Create Biopharma Business, Open New R&D Center

The devicemaker’s biopharma spin-off, Baxalta, will have a global R&D center in Cambridge, Mass. Read More
The Solutions Center